ArticleInvestigational new drugs2021

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.

Marjorie G Zauderer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.